Insight
EGFR+ NSCLC
utsouthwestern.edu

Capmatinib and nazartinib shows promise in EGFR-mutated Lung Cancer resistant to prior treatments

EGFR Positive UK shared a post on X:

“Capmatinib and nazartinib shows promise in patients with EGFR-mutated Lung Cancer resistant to prior treatments.

‘The combination demonstrated anti tumour activity,’ indicating potential as a new treatment strategy.”

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer

Authors:  Enriqueta Felip, Giulio Metro, Ross A Soo, Jürgen Wolf, Benjamin J Solomon, Daniel Sw Tan, Andrea Ardizzoni, Dae Ho Lee, Lecia V Sequist, Fabrice Barlesi, Santiago Ponce-Aix, Delvys Rodriguez Abreu, Maria Rosario Garcia Campelo, Mette Sprauten, Leslie O’Sullivan Djentuh, Nathalie Smith, Aline Jary, Riccardo Belli, Sabine Glaser, Mike Zou, Xiaoming Cui, Monica Giovannini, and James Chih-Hsin Yang. 

Capmatinib and nazartinib shows promise in EGFR-mutated Lung Cancer resistant to prior treatments

Source: EGFR Positive UK/X

anti tumour cancer capmatinib Delvys Rodriguez Abreu EGFR Positive UK EGFR-mutated EGFR-mutated lung cancer Enriqueta Felip Fabrice Barlesi Giulio Metro James Chih-Hsin Yang Leslie O'Sullivan Djentuh Lung cancer Maria Rosario Garcia Campelo Mette Sprauten Monica Giovannini nazartinib OncoDaily OncoDailyCancer Oncology Ross A. Soo Santiago Ponce-Aix Xiaoming Cui